Ivermectin is a semi-synthetic derivative of avermectin, meaning chemists took the natural compound and made one targeted structural change to produce a more effective drug. Avermectin is a family of compounds produced naturally by the soil bacterium Streptomyces avermitilis, while ivermectin is what you get after hydrogenating one specific bond in avermectin B1. That single modification improved the compound’s safety and potency enough to turn it into one of the most widely used antiparasitic drugs in history, earning its discoverers a Nobel Prize in 2015.
How Avermectin Was Found
The story starts in the early 1970s in Japan, where microbiologist Satoshi Ōmura at the Kitasato Institute was systematically isolating soil bacteria and screening them for useful biological activity. In 1974, one particular strain of Streptomyces avermitilis, cultured from a Japanese soil sample, was sent to the laboratories of Merck & Co. in the United States. By 1975, Merck researchers had found that the fermentation broth from this bacterium contained a remarkably potent substance that killed parasitic worms.1PubMed. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents The active ingredients turned out to be a family of closely related compounds, collectively named the avermectins. Eight distinct structures were eventually identified and classified into major and minor components.2PubMed Central. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects
The biosynthesis of avermectin inside the bacterium is governed by a large cluster of genes encoding what are called polyketide synthases, essentially molecular assembly lines that build the compound step by step. The gene cluster contains twelve modular units, organized in two convergently transcribed sets, each catalyzing a specific round of chain elongation to construct the avermectin molecule.3PubMed Central. Organization of the biosynthetic gene cluster for the polyketide anthelmintic macrolide avermectin in Streptomyces avermitilis Understanding this biosynthetic machinery has been important for researchers trying to engineer new derivatives or boost production yields.
The Chemical Tweak That Created Ivermectin
Among the natural avermectins, the most biologically active is avermectin B1, also known as abamectin. William C. Campbell and his team at Merck recognized that a targeted chemical modification could improve the compound’s properties for use as a drug. The modification they chose was selective hydrogenation: they reduced the double bond between carbons 22 and 23, converting it to a single bond. The result, 22,23-dihydroavermectin B1, is what we call ivermectin.4ScienceDirect (Elsevier). Avermectin The change sounds trivially small, but in pharmacology, a single bond alteration can shift a molecule’s stability, absorption, and toxicity profile enough to make the difference between a useful agricultural chemical and a safe systemic drug for animals and people.
Ivermectin actually comes in two slightly different forms, B1a and B1b, which differ by the presence of an ethyl versus a methyl group at one position. Commercial ivermectin is a mixture of the two, with B1a making up at least 80 percent.4ScienceDirect (Elsevier). Avermectin For practical purposes, though, the distinction between B1a and B1b is a manufacturing detail rather than something that changes how ivermectin works in a patient.
How Both Compounds Kill Parasites
Avermectins and ivermectin share the same fundamental mechanism. They target chloride-channel receptors found in the nerve and muscle cells of invertebrates, particularly glutamate-gated chloride channels. When ivermectin binds to these receptors, it forces the channels open, allowing a sustained flood of chloride ions into the cell. That influx locks the cell membrane in a hyperpolarized state, which essentially paralyzes the nerve cell and prevents it from firing.5Scientific Reports. Trapping of ivermectin by a pentameric ligand-gated ion channel upon open-to-closed isomerization For a parasitic worm, this means the muscles controlling feeding and movement stop working, and the parasite dies or is expelled by the host.
This mechanism is the reason both avermectin (as abamectin) and ivermectin are effective against such a broad range of targets, from gastrointestinal roundworms to mites and lice. The glutamate-gated chloride channels they attack are widespread among nematodes and arthropods, giving these compounds their unusually wide spectrum of activity.
Different Jobs for Related Molecules
Despite being chemically close relatives, avermectin and ivermectin have largely gone their separate ways commercially. Abamectin, the natural avermectin B1, became a major agricultural pesticide. It is registered for use as a foliar spray on ornamental plants, citrus, cotton, pears, and various vegetable crops at remarkably low application rates, generally between 5 and 27 grams per hectare.6PubMed. Abamectin as a pesticide for agricultural use Those tiny doses reflect how potent the compound is against plant-feeding mites and insects. Avermectin derivatives more broadly have become some of the most commercially important insecticides and anthelmintics worldwide.7Advanced Agrochem. Research progress of avermectin: A minireview based on the structural derivatization of avermectin
Ivermectin, by contrast, became the flagship drug for treating internal and external parasites in livestock and companion animals. In cattle and sheep, injectable and oral formulations are used against roundworms, lungworms, grubs, lice, and mange mites. Clinical efficacy can reach around 90 percent against susceptible parasites, though the actual results depend heavily on the target species, route of administration, and whether resistance has developed in the local parasite population.8PubMed Central. Ivermectin in veterinary medicine: a narrative review of antiparasitic efficacy, resistance evolution, antiviral evidence, and One Health implications Beyond veterinary medicine, ivermectin crossed into human use, which is where its impact has been most dramatic.
Why Ivermectin Is Safe for Mammals
A question that naturally follows from knowing ivermectin paralyzes invertebrate nerve cells is: why doesn’t it do the same to a dog, a cow, or a person? The answer involves the blood-brain barrier. In mammals, the brain is the organ most vulnerable to ivermectin because it contains GABA-gated chloride channels that the drug could potentially bind to. However, a protein called P-glycoprotein, encoded by the MDR1 gene, acts as a molecular pump at the blood-brain barrier. It actively pushes ivermectin back out of the brain before the drug can accumulate to dangerous levels.9PubMed. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice
This means that at normal therapeutic doses, ivermectin circulates through the body, kills parasites in the gut, skin, and tissues, and gets cleared before reaching concentrations in the brain that would cause neurological problems. The safety margin is large in most mammals, which is why ivermectin has been used so widely. But there is a well-known exception.
The MDR1 Mutation in Herding Breeds
Certain dog breeds, most famously collies, carry a deletion mutation in the MDR1 gene. This four-base-pair deletion creates a premature stop signal in the gene, which means the dog cannot produce functional P-glycoprotein. Without that pump protecting the brain, ivermectin crosses the blood-brain barrier freely and accumulates to toxic levels. Dogs homozygous for the mutation, meaning they inherited the defective gene from both parents, display severe neurotoxicity and can die from standard doses of ivermectin that other dogs tolerate without issue.10PubMed. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene
The mutation is not exclusive to collies. It has been found in Australian shepherds, Shetland sheepdogs, border collies, and several other herding breeds. Genetic testing is now available and widely recommended before prescribing ivermectin or related drugs to these breeds. Dogs that are heterozygous, carrying one normal and one mutant copy, generally do not show increased sensitivity, but many veterinarians still exercise caution with them. Alternative antiparasitic drugs that are not P-glycoprotein substrates can be used instead.
Ivermectin in Human Medicine
Ivermectin’s most transformative role has been in controlling onchocerciasis, commonly known as river blindness, a parasitic disease transmitted by blackfly bites in tropical Africa and parts of Latin America. In 1987, Merck registered ivermectin for human use under the brand name Mectizan and made the extraordinary decision to donate it free of charge to anyone who needed it, for as long as needed. Over the following decades, more than 800 million doses were distributed to over 80 million people, dramatically reducing the incidence and severity of the disease.11PubMed Central. Importance of ivermectin to human onchocerciasis: past, present, and the future
The economic impact was substantial. Analyses of the Onchocerciasis Control Program in West Africa calculated a net present value of $485 million over 39 years, while the African Program for Onchocerciasis Control yielded a net present value of $88 million over 21 years. Cost-effectiveness estimates put ivermectin distribution at roughly $14 to $30 per disability-adjusted life year prevented, comparable to other high-priority global health interventions. These numbers are sensitive to the fact that the drug itself was donated; the market value of Merck’s annual donation alone outweighed the calculated benefits of both programs.12PubMed. Economic evaluation of Mectizan distribution The Mectizan Donation Program has been described as a model for public-private partnerships in global health, and it laid groundwork for broader efforts to address neglected tropical diseases.13PubMed. The Mectizan Donation Program: 20 years of successful collaboration – a retrospective
Ivermectin was approved by the U.S. FDA in 1996 for strongyloidiasis and onchocerciasis, though off-label use for other parasitic conditions has been common. It is also used topically against head lice and rosacea. The 2015 Nobel Prize in Physiology or Medicine was awarded jointly to Satoshi Ōmura and William C. Campbell for their work on avermectin and ivermectin, alongside Youyou Tu for her discovery of artemisinin against malaria.14Proceedings of the National Academy of Sciences (PNAS). Profile of William C. Campbell, Satoshi Ōmura, and Youyou Tu, 2015 Nobel Laureates in Physiology or Medicine
Parasite Resistance to Avermectins
With decades of heavy use, resistance to ivermectin and related avermectins has become a growing problem, particularly in livestock parasites. The barber’s pole worm, Haemonchus contortus, is the best-studied example. Resistance has been documented in sheep and goat populations across Africa, South America, and Asia, and the mechanisms appear to be multiple rather than a single genetic change.15International Journal for Parasitology. Evidence of multiple mechanisms of avermectin resistance in Haemonchus contortus—comparison of selection protocols
One recently discovered mechanism involves the parasite’s own gut bacteria. Researchers found that a symbiotic bacterium, Stenotrophomonas maltophilia, living within Haemonchus contortus can metabolize ivermectin, converting it into less active breakdown products. When the bacterium was depleted, the worms became more susceptible to ivermectin; when it was reintroduced, tolerance partially returned.16PubMed Central. Symbiotic Stenotrophomonas maltophilia is associated with ivermectin resistance in the parasitic nematode Haemonchus contortus via metabolic detoxification This finding complicates the picture because it means resistance is not always about the parasite’s own genes. Its microbial partners can lend a hand.
Rising resistance has pushed researchers and veterinarians toward strategies like targeted selective treatment, where not every animal in a herd is dosed. The idea is to leave a portion of the parasite population unexposed to the drug, maintaining a pool of susceptible worms that dilute the resistant ones when they breed.
Environmental Costs of Ivermectin Use in Livestock
Ivermectin does not vanish after it passes through a treated animal. A significant fraction is excreted in the dung, and the concentrations that end up in cattle pats are high enough to harm the insects that colonize and break down that dung. This matters because dung beetles and other coprophagous insects perform critical ecosystem services: they bury dung, aerate soil, recycle nutrients, and suppress pest flies.
A study in Eastern Ethiopia found that ivermectin residues in cattle dung suppressed dung beetle populations in the initial weeks after treatment, while treated dung attracted heavier termite infestations.17PubMed Central. Experimental study on the effect of Ivermectin on cattle dung faunas in Eastern Ethiopia More controlled experiments have quantified the damage: at ivermectin concentrations between 250 and 500 parts per billion in dung, emergence of the next generation of dung beetles dropped to as low as 5 to 20 percent, compared with 68 to 88 percent emergence in untreated dung.18Science of The Total Environment. Experimental evidence that dung beetles benefit from reduced ivermectin in targeted treatment of livestock parasites Most of the mortality hit the egg and first-instar larval stages. These findings support the targeted selective treatment approach as a way to create dung-pat refuges where beetles can reproduce safely.
Comparative toxicity research has also shown that not all avermectin-class drugs are equally damaging. Ivermectin is roughly six times more toxic to adult dung beetles than moxidectin, another macrocyclic lactone used in livestock.19Scientific Reports. First assessment of the comparative toxicity of ivermectin and moxidectin in adult dung beetles: Sub-lethal symptoms and pre-lethal consequences Even sub-lethal exposure to ivermectin residues in dung can impair beetles’ ability to detect food, communicate, and move, so the ecological impact extends beyond outright mortality.
How Delivery Method Changes What Ends Up in the Environment
The route by which an animal receives ivermectin has a surprisingly large effect on how much drug ends up in its dung and for how long. In cattle treated with a pour-on formulation, fecal ivermectin concentrations spiked to roughly 18.5 micrograms per gram of dry dung weight within two days, then fell off quickly. Injectable ivermectin produced a much lower fecal peak of about 1.2 micrograms per gram at three days. A sustained-release bolus, by contrast, delivered a steady fecal concentration of around 3 to 4 micrograms per gram over weeks.20International Journal for Parasitology. Persistence of ivermectin in plasma and faeces following treatment of cows with ivermectin sustained-release, pour-on or injectable formulations For dung beetles and other non-target organisms, the pour-on formulation creates a brief but intense toxic window, while the bolus creates a lower but more prolonged exposure. Neither is ideal, but understanding these trade-offs helps farmers and veterinarians make more informed choices.
Research into new delivery technologies, including lipid nanocapsules designed to alter how ivermectin distributes through the body, aims to improve efficacy while potentially reducing the amount of drug that reaches the environment through feces.21PubMed. Ivermectin-loaded lipid nanocapsules: toward the development of a new antiparasitic delivery system for veterinary applications These approaches are still largely experimental, but they reflect growing awareness that the environmental side effects of livestock deworming need engineering solutions, not just management guidelines.
Ivermectin’s Detour into Antiviral Research
Starting around 2012, laboratory studies showed that ivermectin could block a specific protein-transport pathway used by several viruses. The drug inhibits the importin α/β pathway, which many viruses rely on to shuttle their proteins into the host cell’s nucleus. In cell-culture experiments, ivermectin demonstrated the ability to inhibit replication of HIV-1 and dengue virus through this mechanism.22PubMed Central. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus Mechanistically, ivermectin binds to the importin α component, preventing it from docking with importin β1, which blocks viral proteins from entering the nucleus and lets the cell mount its own antiviral defenses.23The Journal of Antibiotics. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review
This laboratory finding became enormously controversial during the COVID-19 pandemic, when ivermectin was promoted as a treatment for SARS-CoV-2 infection. The core problem was one of dose: the concentrations needed to inhibit viral replication in a lab dish were far higher than what can safely be achieved in a human body at approved doses. Large randomized clinical trials subsequently failed to show meaningful benefit for COVID-19 patients. The episode is a useful reminder that a compound’s activity in a petri dish does not automatically translate to clinical effectiveness, and that ivermectin’s proven value remains firmly in the antiparasitic domain where it has decades of real-world evidence behind it.
The Expanding Family of Avermectin Derivatives
Ivermectin was the first and most famous derivative of avermectin, but it is far from the only one. The same parent compounds have been chemically modified to create doramectin (used mainly in cattle), eprinomectin (designed to have no milk-withdrawal period, making it suitable for dairy cattle), selamectin (the active ingredient in some flea-and-heartworm preventives for dogs and cats), and moxidectin (technically a milbemycin rather than an avermectin, but closely related and often grouped with them).2PubMed Central. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects Each derivative was engineered to optimize for a particular niche: faster absorption, longer duration, lower toxicity to non-target species, or compatibility with food-animal regulations.
Ongoing research into structural modifications of the avermectin scaffold continues to produce new candidates. Some aim for improved potency against resistant parasite strains. Others focus on reducing environmental persistence or broadening the spectrum of activity against insect pests in agriculture.7Advanced Agrochem. Research progress of avermectin: A minireview based on the structural derivatization of avermectin The original soil bacterium that Ōmura isolated from a Japanese golf course more than fifty years ago has spawned a whole pharmacological family, and the branches of that family tree keep growing.